What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and ...

An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their ...

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...